Medtronic launches yet another back pain neurostim study

April 11, 2013 by Arezu Sarvestani

Medical device company Medtronic continues to battle for its position in the market for neurostimulation systems that treat pain with a new clinical study of treatments for chronic back pain.

chronic back pain illustration

Medtech titan Medtronic (NYSE:MDT) enrolled the initial patients in its SubQStim II pivotal clinical trial, evaluating the use of peripheral nerve stimulation in treatment of chronic back pain.

The new study is the latest in a handful of neurostimulation trials launched by the medical device giant as it continues to battle rivals in the market for neurostimulation systems that treat chronic pain. 

Patients enrolled in the SubQStim II trial received implanted electrical leads under the skin of the lower back. The leads connect to an electrical pulse generator that delivers mild pulses of energy to interrupt pain signal on their way to the brain.

Sign up to get our free newsletters delivered right to your inbox.

The randomized, multi-center clinical study will enroll up to 323 patients at up to 30 centers in the U.S. Patients will be randomized to either a control group or neurostimulation treatment for 3 months and follow-up will continue for up to 5 years, according to a Medtronic press release.

"Study findings will provide an unprecedented understanding of how leads placed in the subcutaneous tissue layer work with neurostimulation devices to help patients manage their chronic back pain," principal investigator Dr. Yeshvant Navalgund said in prepared remarks.

Comments